Postoperative Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma: Friend or Foe? a Meta Analysis

Wen Chen,Tao Ma,Xueli Bai,Tingbo Liang

DOI: https://doi.org/10.1016/j.hpb.2019.10.1683

IF: 3.842

2019-01-01

HPB

Abstract:Introduction: This study aimed to systematically evaluate the patients with hepatocellular carcinoma (HCC) who could benefit from PA-TACE and who may not suitable for PA-TACE. Method: In this systematic review and meta-analysis, we searched PubMed, EMBASE and Cochrane Library for randomized controlled trials (RCTs) and non-RCTs until February 10, 2019. Studies comparing PA-TACE with curative resection alone were included. Overall survival (OS) and disease-free survival (DFS) results were extracted and converted to a hazard ratios (HRs) with 95% confidence intervals (95%CIs). Result: A total of 38 studies (10 RCTs and 28 non-RCTs) involving 10799 patients were included for analysis in our study. In the meta-analysis of all patients, PA-TACE was associated with an increased OS [HR, 0.71 (95% CI, 0.66-0.77); p<0.00001] and DFS [HR, 0.78 (95% CI, 0.74-0.82); p<0.00001]. Subgroup analyses in patients with microvascular invasion (MVI), tumor diameter >5cm or multinodular tumors, PA-TACE also demonstrated improved OS and DFS compared to curative resection alone. Nevertheless, in patients without MVI, PA-TACE showed no effective in OS [HR, 1.14 (95% CI, 0.85-1.53); p=0.37] and even worse DFS than curative resection alone [HR, 1.20 (95% CI, 1.03-1.39); p=0.02]. In patients with tumor diameter≤5cm or unimodular tumor, OS and DFS were comparable between PA-TACE and curative resection alone groups. Conclusion: This updated meta-analysis indicated that PA-TACE was beneficial in patients with high risk of postoperative recurrence including tumor diameter >5cm, multinodular tumors and MVI positive, but not in patients with low risk of postoperative recurrence. PA-TACE may even promote the postoperative recurrence in patient without MVI.